Cerebroprotective effect of lamotrigine after focal ischemia in rats

Stroke. 1995 Jan;26(1):117-21; discussion 121-2. doi: 10.1161/01.str.26.1.117.

Abstract

Background and purpose: Glutamate receptor antagonists are protective in animal models of focal cerebral ischemia. Lamotrigine (3,5-diamino-6-[2,3-dichlorophenyl]-1,2,4-triazine) is an anticonvulsant drug that blocks voltage-gated sodium channels and inhibits the ischemia-induced release of glutamate. We describe the cerebroprotective effect of lamotrigine (as the isethionate salt) after middle cerebral artery occlusion in rats.

Methods: Neurological deficit and infarct volume (visualized by the lack of reduction of 2,3,5-triphenyltetrazolium chloride) 24 hours after permanent left middle cerebral artery occlusion were studied in Fischer rats (n = 8 per group per dose).

Results: Lamotrigine at 20 mg/kg i.v. over 10 minutes administered immediately after middle cerebral artery occlusion reduced total infarct volume by 31% and cortical infarct volume by 52%. Lamotrigine at 8 mg/kg i.v. over 10 minutes reduced cortical infarct volume by 38%. Lamotrigine at 50 mg/kg i.v. for 10 minutes was not cerebroprotective and induced a decrease of 29 +/- 15 mm Hg in mean arterial blood pressure (P < .05, n = 8). The optimum dose of lamotrigine (20 mg/kg i.v. over 10 minutes) when administered with a 1-hour delay after middle cerebral artery occlusion reduced cortical infarct volume by 41%. Lamotrigine (20 mg/kg i.v. over 10 minutes) with a 2-hour delay after middle cerebral artery occlusion was ineffective. Neurological deficits after 24 hours were improved after immediate treatment with lamotrigine at 20 mg/kg i.v. over 10 minutes.

Conclusions: The cerebroprotective effect of lamotrigine in rats is limited to a narrow dose range between 8 and 20 mg/kg. Lamotrigine or analogous compounds may be useful when given shortly after the onset of stroke.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Cerebral Infarction / drug therapy*
  • Cerebral Infarction / pathology
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Lamotrigine
  • Male
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Rats
  • Rats, Inbred F344
  • Sodium Channels / drug effects
  • Triazines / administration & dosage
  • Triazines / pharmacology
  • Triazines / therapeutic use*

Substances

  • Excitatory Amino Acid Antagonists
  • Piperazines
  • Pyrimidines
  • Sodium Channels
  • Triazines
  • 5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate
  • sipatrigine
  • Lamotrigine